Biotechnology

Everfur Launches Fur-Forward Diagnostics Kit: Pioneering Pet Health Monitoring With Advanced Metabolomics

May 22, 2024 10:00 AM

NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Everfur announces the debut of its groundbreaking product: the Fur-Forward Diagnostics Kit. With just a sample of your pets' fur, Everfur analyzes their unique molecules to help determine fur quality, brain health, digestion, immunity, and potential disease risks. Inspired by the journey of Daisy, the beloved feline companion of Fayzan Chaudhry, CEO of Everfur and a PhD Candidate, this innovative...

Read more

Archetype Discovers Drugs to Improve Patient Outcomes in Lung Cancer Using a Generative Chemogenomic Screen of Billions of Compounds

May 22, 2024 10:00 AM

Archetype Therapeutics, an AI-native company pioneering the integrative use of generative chemogenomics in drug discovery, announced today that it has discovered compounds for the treatment of early-stage lung adenocarcinoma (esLUAD) by screening billions of compounds from the Enamine REAL Space chemical library and other libraries. These pre-lead drugs are being validated in vitro and in vivo through Archetype-sponsored research conducted at...

Read more

TISSIUM Selected for the French Tech 120 Program

May 22, 2024 8:45 AM

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, confirms its selection for the fifth year in a row in the French Tech 120 Program by joining the class of 2024. Launched in 2019 by the Mission French Tech, the French Tech 120 is a program from the Government to support the 120 most promising French start-ups, who have the potential to become world-class technology leaders. TISSIUM...

Read more

Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders

May 22, 2024 8:12 AM

No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence Investor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential Impact on PTSD, Depression, Anxiety, Addiction, and Obesity NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the complete safety data set from the single...

Read more

Tharimmune Announces 1-for-15 Reverse Stock Split

May 22, 2024 7:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / May 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock after the close of trading on The Nasdaq Capital Market ("Nasdaq") on May 24, 2024. Tharimmune's...

Read more

Next Gen Diagnostics and Vanderbilt Report the Use of Whole Genome Sequencing to Detect Transmission of Infection in a Neonatal Intensive Care Unit

May 21, 2024 6:30 PM

WEST PALM BEACH, FL / ACCESSWIRE / May 21, 2024 / Next Gen Diagnostics (NGD) and a team at Vanderbilt University Medical Center (VUMC) today announced the results of a study reporting that comparison of the whole genome sequence (WGS) of bacterial pathogens obtained from surveillance of infants in a neonatal intensive care unit (NICU) revealed substantial transmission of infection not detected by conventional infection control procedures. The...

Read more

Adolore BioTherapeutics Outlines Strategy for its Next Generation, Disease-Modifying, Non-Opioid Analgesic Gene Therapies for the Treatment of Chronic Pain

May 21, 2024 10:00 AM

Development program for the treatment of osteoarthritis (OA) chronic knee pain is fully funded through the first-in-human clinical study by a UG3/UH3 grant awarded by NIH/NINDS HEAL program Ongoing progress with IND-enabling studies of ADLR-1001 gene therapy for the treatment of OA chronic knee pain; Additional translational data expected before year-end Plans for data presentations at prominent scientific congresses and publications in premier...

Read more

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

May 21, 2024 9:15 AM

Team composed of former FDA officials and key clinical and regulatory opinion leaders to help provide insight in preparation for collaboration with FDA NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has formed an Advisory Committee to provide guidance as the company prepares...

Read more

NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform

May 21, 2024 9:00 AM

CLEVELAND, OH / ACCESSWIRE / May 21, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a pioneering biomedical company developing innovative immunotherapies for brain tumor patients, today announced it has submitted a provisional patent for new intellectual property developed at Cedars-Sinai to advance the Company's immunotherapy platform. The patent pertains to the use of a specific protein, known as IDH1, which helps facilitate metabolism in cells in...

Read more

Center Point Bio-Tech Signs National Distribution Agreement

May 20, 2024 12:00 PM

LAS VEGAS, NV / ACCESSWIRE / May 20, 2024 / In anticipation of commercial launch of the AlphaION Point of Care diagnostic platform, Center Point Bio-Tech, LLC ("CP Bio") entered into a non-exclusive distribution agreement with a well-known and highly respected veterinary distributor with over 60 years of sales excellence and logistics expertise to sell and distribute products to veterinary hospitals. "Center Point Bio-Tech's development of...

Read more

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

May 20, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product. PF614-MPAR is the Company's...

Read more

Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis

May 20, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO) Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment. The therapy was safe and well tolerated with no treatment-related serious adverse events. Biomarker analysis reflected an increase in plasma MMP-13 and a trend of decreased plasma TGFβ1, consistent with the mechanism of action. The data were orally presented at...

Read more

QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency

May 17, 2024 2:00 AM

QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality Control Laboratories issued by the Swedish Medical Products Agency (Läkemedelsverket). QuTEM is thereby authorized to perform critical quality control analysis essential for the release of medicines to...

Read more

AppYea Chairman Bary Molchadsky Demonstrates Confidence by Converting Debt to Warrants with a Strike Price Set at a 250% Premium to Current Market Price of the Company’s Common Stock

May 16, 2024 3:30 PM

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / AppYea Inc. (OTCQB:APYP), developer of an innovative wearable monitoring solution to monitor and treat sleep apnea and snoring, today announced the conversion of the majority of debt owed to its Chairman, Boris (Bary) Molchadsky, who converted approximately $140,000 of debt into AppYea warrants with a strike price of $0.07 per share, reflecting a premium of more than 250% over the current market price...

Read more

Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels

May 16, 2024 10:00 AM

Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediate profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain Company continuing...

Read more

Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences

May 16, 2024 9:00 AM

MIAMI, FL / ACCESSWIRE / May 16, 2024 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of neurological treatments, announces the Company's continued inability to undertake certain corporate actions (name and symbol change, M&A, Reverse Split etc.) due to uncorrectable regulatory filing deficiencies from over a...

Read more

BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in NHL

May 14, 2024 10:25 AM

First data for the SC arm: 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients. Further updates from the IV arm; a fifth CR has been observed, adding to a total of 5 CR, 1 PR and 6 SD out of 17 evaluable patients. Data to be presented at the European Hematology Association, June 13-16, 2024. BI-1206 is developed to re-establish the clinical effect of existing cancer treatments such as rituximab...

Read more

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

May 14, 2024 9:15 AM

Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1] Please see Important Safety Information and study design below NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug...

Read more

Vicore Expands and Strengthens its Board of Directors

May 14, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann...

Read more

Ensysce Biosciences Reports First Quarter 2024 Financial Results

May 13, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the first quarter ended March 31, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "In the first quarter of 2024, we continued to accelerate the...

Read more